Literature DB >> 25552648

Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.

Yuyu Niu1, Xiangyu Guo2, Yongchang Chen1, Chuan-En Wang3, Jinquan Gao2, Weili Yang2, Yu Kang1, Wei Si4, Hong Wang1, Shang-Hsun Yang5, Shihua Li3, Weizhi Ji6, Xiao-Jiang Li7.   

Abstract

Parkinson's disease (PD) is an age-dependent neurodegenerative disease that can be caused by genetic mutations in α-synuclein (α-syn) or duplication of wild-type α-syn; PD is characterized by the deposition of α-syn aggregates, indicating a gain of toxicity from accumulation of α-syn. Although the major neuropathologic feature of PD is the degeneration of dopaminergic (DA) neurons in the substantia nigra, non-motor symptoms including anxiety, cognitive defect and sleep disorder precede the onset of motor impairment, and many clinical symptoms of PD are not caused by degeneration of DA neurons. Non-human primate models of PD are important for revealing the early pathology in PD and identifying effective treatments. We established transgenic PD rhesus monkeys that express mutant α-syn (A53T). Six transgenic A53T monkeys were produced via lentiviral vector expressing A53T in fertilized monkey eggs and subsequent embryo transfer to surrogates. Transgenic A53T is expressed in the monkey brain and causes age-dependent non-motor symptoms, including cognitive defects and anxiety phenotype, without detectable sleeping disorders. The transgenic α-syn monkeys demonstrate the specific early symptoms caused by mutant α-syn and provide insight into treatment of early PD.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25552648      PMCID: PMC4375423          DOI: 10.1093/hmg/ddu748

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  26 in total

1.  Transgenic rhesus monkeys produced by gene transfer into early-cleavage-stage embryos using a simian immunodeficiency virus-based vector.

Authors:  Yuyu Niu; Yang Yu; Agnieszka Bernat; Shihua Yang; Xiechao He; Xiangyu Guo; Dongliang Chen; Yongchang Chen; Shaohui Ji; Wei Si; Yongqin Lv; Tao Tan; Qiang Wei; Hong Wang; Lei Shi; Jean Guan; Xuemei Zhu; Marielle Afanassieff; Pierre Savatier; Kang Zhang; Qi Zhou; Weizhi Ji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-24       Impact factor: 11.205

Review 2.  Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

Authors:  K Ray Chaudhuri; Anthony H V Schapira
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 3.  Non-motor symptoms in Parkinson's disease.

Authors:  Ariane Park; Mark Stacy
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

Review 4.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

5.  Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.

Authors:  Andisheh Eslamboli; Marina Romero-Ramos; Corinna Burger; Tomas Bjorklund; Nicholas Muzyczka; Ronald J Mandel; Harry Baker; Rosalind M Ridley; Deniz Kirik
Journal:  Brain       Date:  2007-02-15       Impact factor: 13.501

Review 6.  Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

7.  Real-time PCR to determine transgene copy number and to quantitate the biolocalization of adoptively transferred cells from EGFP-transgenic mice.

Authors:  Molishree Joshi; H Keith Pittman; Carl Haisch; Kathryn Verbanac
Journal:  Biotechniques       Date:  2008-09       Impact factor: 1.993

8.  Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease.

Authors:  Chuan-En Wang; Suzanne Tydlacka; Adam L Orr; Shang-Hsun Yang; Rona K Graham; Michael R Hayden; Shihua Li; Anthony W S Chan; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2008-06-16       Impact factor: 6.150

Review 9.  Molecular and clinical prodrome of Parkinson disease: implications for treatment.

Authors:  Anthony H V Schapira; Eduardo Tolosa
Journal:  Nat Rev Neurol       Date:  2010-05-18       Impact factor: 42.937

Review 10.  Genetics of Parkinson's disease and parkinsonism.

Authors:  John Hardy; Huaiban Cai; Mark R Cookson; Katrina Gwinn-Hardy; Andrew Singleton
Journal:  Ann Neurol       Date:  2006-10       Impact factor: 10.422

View more
  34 in total

1.  Monkey kingdom.

Authors:  David Cyranoski
Journal:  Nature       Date:  2016-04-21       Impact factor: 49.962

2.  Opportunities and challenges in modeling human brain disorders in transgenic primates.

Authors:  Charles G Jennings; Rogier Landman; Yang Zhou; Jitendra Sharma; Julia Hyman; J Anthony Movshon; Zilong Qiu; Angela C Roberts; Anna Wang Roe; Xiaoqin Wang; Huihui Zhou; Liping Wang; Feng Zhang; Robert Desimone; Guoping Feng
Journal:  Nat Neurosci       Date:  2016-08-26       Impact factor: 24.884

Review 3.  Generation of genetically engineered non-human primate models of brain function and neurological disorders.

Authors:  Jung Eun Park; Afonso C Silva
Journal:  Am J Primatol       Date:  2018-12-26       Impact factor: 2.371

Review 4.  Progress in developing transgenic monkey model for Huntington's disease.

Authors:  Brooke R Snyder; Anthony W S Chan
Journal:  J Neural Transm (Vienna)       Date:  2017-11-10       Impact factor: 3.575

Review 5.  Modeling autism in non-human primates: Opportunities and challenges.

Authors:  Hui Zhao; Yong-Hui Jiang; Yong Q Zhang
Journal:  Autism Res       Date:  2018-03-23       Impact factor: 5.216

Review 6.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

Review 7.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 8.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 9.  α-Synuclein and nonhuman primate models of Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neurosci Methods       Date:  2015-08-03       Impact factor: 2.390

10.  Nonhuman Primate Models of Neurodegenerative Disorders.

Authors:  Marina E Emborg
Journal:  ILAR J       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.